Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
Diabesity is a new term for obesity-dependent diabetes, which is also associated with cardiovascular and other comorbidities with rising epidemic. Traditional treatments (sulfonylureas and thiazolidinediones) of diabetes are associated with weight gain, except metformin. Newer agents such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium glucose co-transporter 2 inhibitors (SGLT2i) are causing a modest weight reduction, whereas dipeptidyl peptidase-4 inhibitors (DPP-4i) are weight neutral. Oxyntomodulin, a native GLP-1/glucagon receptor agonist produced a superior weight loss and antihyperglycemic effects in obese mice and humans. Recent findings with synthetic dual GLP-1/glucagon receptor agonists have shown a good weight loss and antihyperglycemic profile in diet-induced obese (DIO) mice. Targeting combinations of GLP-1 receptor and glucagon receptor simultaneously with a single peptide may be the better strategy to achieve marked weight loss and considerable glycemic control in diabesity. Cardiovascular safety is very important with new antidiabetic agents due to rosiglitazone controversy. Current on-going clinical trials will clarify the cardiovascular effects of incretin-based therapies in near future. Based on current knowledge and rapid progress in the field, there is a strong possibility that the GLP-1/glucagon receptor co-agonists will likely be the new therapeutic treatment for diabesity for decades to come.
Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA. Electronic address: drhiteshsoni@gmail.com.
Hitesh
H
Soni
D000818:Animals; D006801:Humans; D051379:Mice; D051381:Rats; D002986:Clinical Trials as Topic; D048909:Diabetes Complications / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000077270:Exenatide; D008820:Mice, Obese; D009765:Obesity / Q000150:complications; D053772:Oxyntomodulin / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D014158:Transcription, Genetic; D014688:Venoms / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
D054873:Dipeptidyl-Peptidase IV Inhibitors; D000077270:Exenatide; D053772:Oxyntomodulin; D010455:Peptides; D011994:Recombinant Proteins; D000077154:Rosiglitazone; D045162:Thiazolidinediones; D014688:Venoms; D018027:Receptors, Glucagon; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
Co-agonist; Diabesity; Glucagon; Glucagon-like peptide-1 (GLP-1); Oxyntomodulin